Table 1.
General characteristics of patients
| Patients | Age, y | Sex | Disease | HSCT or CAR T cell | Previous contact with PC team | Referred by | Hematology follow-up | Survival after first consultation, d | Oncologic treatment | Number of consultations | Referrals to emergency department | Number of hospitalizations and length of stay, d | Time between consultation and hospitalization, d | Blood transfusions | Place of death |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P1 | 78 | F | AML | No | No | Hematologist | Yes | 86 | No | 1 | 1 | 2 (7 + 13) | 43 | 1 | PC department |
| P2 | 73 | F | Diffuse B lymphoma | No | No | Hematologist | No | 112 | Yes, radiotherapy | 2 | 1 | 1 (5) | 107 | 0 | Medical department |
| P3 | 80 | M | Myeloma | No | No | Hematologist | Yes | 8 | No | 1 | 1 | 1 (7) | 1 | 0 | Medical department |
| P4 | 84 | F | AML | No | No | Hematologist | No | 33 | No | 1 | 0 | 0 | 0 | Home | |
| P5 | 82 | M | Diffuse B lymphoma | No | Yes | PC department | No | 26 | Yes, radiotherapy | 1 | 0 | 0 | 0 | Home | |
| P6 | 62 | M | Myeloma | Yes | No | Hematologist | No | 59 | No | 2 | 0 | 0 | 3 | Home | |
| P7 | 79 | F | AML | No | No | Hematologist | Yes | 97 | No | 2 | 0 | 0 | 0 | Home | |
| P8 | 40 | F | Hodgkin lymphoma | Yes | No | Hematologist | Yes | 70 | Yes, target therapy | 3 | 1 | 1 (1) | 69 | 0 | PC department |
| P9 | 83 | M | MDS | No | Yes | Hematologist | Yes | 63 | No | 3 | 1 | 2 (2 + 5) | 2 | 3 | PC department |
| P10 | 88 | M | Mantle cell lymphoma | No | No | Hematologist | No | 335 | Yes, target therapy | 5 | 0 | 0 | 0 | 0 | |
| P11 | 88 | M | Hodgkin lymphoma | No | No | Hematologist | No | 24 | No | 1 | 0 | 1 (23) | 1 | 0 | PC department |
| P12 | 88 | F | AML | No | No | Hematologist | No | 9 | No | 1 | 0 | 1 (9) | 0 | 0 | PC department |
| P13 | 81 | F | Myeloma | No | No | Hematologist | Yes | 101 | Yes, IV chemotherapy | 2 | 1 | 1 (2) | 99 | 1 | Emergency department |
| P14 | 60 | M | T lymphoma | No | No | Hematologist | Yes | 186 | Yes, oral chemotherapy | 4 | 1 | 1 (25) | 166 | 2 | |
| P15 | 80 | M | Mantle cell lymphoma | No | No | Hematologist | No | 32 | Yes, oral chemotherapy | 1 | 0 | 1 (18) | 13 | 0 | PC department |
| P16 | 82 | F | Hodgkin lymphoma | No | No | Hematologist | Yes | 159 | Yes, oral chemotherapy | 1 | 0 | 0 | 0 | ||
| P17 | 85 | M | T lymphoma | No | No | Hematologist | Yes | 123 | No | 1 | 0 | 0 | 0 | ||
| P18 | 92 | M | Burkitt lymphoma | No | No | Hematologist | No | 109 | Yes, targeted therapy | 1 | 0 | 0 | 0 | Home | |
| P19 | 63 | F | Diffuse B lymphoma | Yes | No | Hematologist | No | 122 | No | 3 | 0 | 1 (12) | 98 | 2 | Home |
| P20 | 52 | F | Diffuse B lymphoma | No | No | Hematologist | Yes | 109 | Yes, targeted therapy | 1 | 0 | 0 | 0 | ||
| P21 | 85 | F | AML | No | No | Hematologist | No | 14 | Yes, oral chemotherapy | 1 | 1 | 1 (10) | 4 | 0 | Medical department |
| P22 | 41 | M | ALL | Yes | No | Hematologist | No | 28 | No | 2 | 0 | 1 (1) | 28 | 2 | PC department |
| P23 | 93 | F | Diffuse B lymphoma | No | No | Hematologist | Yes | 18 | Yes, oral chemotherapy | 1 | 0 | 0 | 0 |
ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; F, female; HSCT, allogeneic stem cell transplantation; M, male; MDS, myelodysplastic syndrome.